Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992571 | 0.87 | BACE1 (0.40) | BACE1 | |
| SCHEMBL21991815 | 0.84 | FBP1 (0.40) | HSD17B10LMNAMAPK1BACE1 | |
| SCHEMBL21992584 | 0.83 | PHGDH (0.37) | BACE1 | |
| SCHEMBL21991741 | 0.81 | PPARA (0.54) | LMNAMAPK1HTTRAB9A | |
| SCHEMBL14447040 | 0.79 | MRGPRX4 (0.45) | RAB9A | |
| SCHEMBL21991809 | 0.78 | CA1 (0.47) | HSD17B10LMNAMAPK1HTT | |
| SCHEMBL21992541 | 0.77 | PPARA (0.41) | — | |
| SCHEMBL21991239 | 0.77 | MEN1 (0.42) | BACE1 | |
| SCHEMBL21991836 | 0.74 | LMNA (0.54) | LMNA | |
| SCHEMBL21991462 | 0.73 | HTT (0.46) | TAS2R14LMNAMAPK1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | HSD17B10 1236/4885TAS2R14 2381/4885LMNA 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.